Fly News Breaks for February 28, 2020
Feb 28, 2020 | 09:04 EDT
B. Riley FBR analyst Mayank Mamtani raised the firm's price target on Novavax to $15 from $12 and keeps a Buy rating on the shares. The company on Wednesday reported progress in its development of a novel vaccine to protect against coronavirus disease, Mamtani tells investors in a research note. He believes Novavax is among the leading biopharma companies with appropriate R&D capabilities to respond to this emerging medical need for a therapeutic or preventative drug.
News For NVAX From the Last 2 Days
There are no results for your query NVAX